Published January 15, 2024 | Version v1
Journal article Open

Interplay of adiponectin and resistin in type 2 diabetes: Implications for insulin resistance and atherosclerosis

Authors/Creators

  • 1. The Hashemite University, Zarqa, Jordan
  • 2. Zarqa University, Zarqa, Jordan
  • 3. Jordan University, Amman, Jordan

Description

Aim: The study aims to investigate the association between type 2 diabetes and adipokines, particularly resistin and adiponectin, in insulin resistance. It also explores the potential of the resistin to adiponectin ratio as an indicator for these conditions

Methods: This research involved 198 participants, including 100 patients with type 2 diabetes and 98 controls. It focused on measuring various biochemical parameters like HbA1c, fasting plasma glucose, lipid profiles (low-density lipoprotein, oxidized low-density lipoprotein, triglyceride, total cholesterol), and adipokines (resistin and adiponectin). The study utilized the Homeostasis Model Assessment of Insulin Resistance and Triglyceride-Glucose index to evaluate insulin resistance.

Results: Type 2 diabetic patients exhibited higher levels of HbA1c, fasting plasma glucose, lipid profiles, and resistin, but lower adiponectin levels compared to controls. Adiponectin showed a negative correlation with insulin resistance, while resistin demonstrated a positive correlation. Both adipokines significantly related to atherogenic markers, with adiponectin offering protection against atherosclerosis and resistin augmenting it.

Conclusion: The findings underscore the complex roles of resistin and adiponectin in the pathophysiology of type 2 diabetes, insulin resistance. The resistin to adiponectin ratio could be a useful biomarker for insulin resistance. These insights suggest potential therapeutic strategies for treating diabetes and preventing its complications.

Files

PHAR_article_114863.pdf

Files (365.4 kB)

Name Size Download all
md5:aa9c55a43897faef415db5955f8029f9
255.4 kB Preview Download
md5:0cbe03fd9fdd594996964f41b97eeef9
110.0 kB Preview Download

Additional details

Cites
Publication: 10.3892/etm.2013.1347 (DOI)
Publication: 10.2337/dc18-S002 (DOI)
Publication: 10.2174/1573403X17666210729101120 (DOI)
Publication: 10.21203/RS.3.RS-37122/V1 (DOI)
Publication: 10.1590/S1807-59322011000700002 (DOI)
Publication: 10.1161/01.ATV.0000191663.12164.77 (DOI)
Publication: 10.1016/j.molmet.2014.01.005 (DOI)
Publication: 10.1016/j.cmet.2011.07.015 (DOI)
Publication: 10.3390/ijms22052639 (DOI)
Publication: 10.1210/er.2001-0039 (DOI)
Publication: 10.1016/j.jaci.2005.02.023 (DOI)
Publication: 10.1007/978-3-031-13177-6_8 (DOI)
Publication: 10.1016/j.metabol.2022.155381 (DOI)
Publication: 10.1007/s11883-012-0228-1 (DOI)
Publication: 10.1016/j.metabol.2022.155379 (DOI)
Publication: 10.1016/J.ATHEROSCLEROSIS.2006.08.002 (DOI)
Publication: 10.1016/S0002-9149(03)00611-8 (DOI)
Publication: 10.1161/01.HYP.0000129281.03801.4B (DOI)
Publication: 10.1007/s00125-002-1009-0 (DOI)
Publication: 10.5551/jat.RV17014 (DOI)
Publication: 10.1073/pnas.0305905101 (DOI)
Publication: 10.2174/187153012800493468 (DOI)
Publication: 10.1016/j.tem.2021.06.001 (DOI)
Publication: 10.1038/s41598-021-82053-2 (DOI)
Publication: 10.1080/10623320701617225 (DOI)
Publication: 10.1196/annals.1361.050 (DOI)
Publication: 10.1016/j.atherosclerosis.2006.05.039 (DOI)
Publication: 10.2337/db07-1419 (DOI)
Publication: 10.3390/biomedicines9080915 (DOI)
Publication: 10.2337/DB05-1322 (DOI)
Publication: 10.1161/STROKEAHA.107.485540 (DOI)
Publication: 10.1038/nri2921 (DOI)
Publication: 10.1038/emm.2014.38 (DOI)
Publication: 10.1161/01.CIR.0000155620.10387.43 (DOI)
Publication: 10.1111/J.1365-2265.2006.02658.x (DOI)
Publication: 10.2174/092986712803833164 (DOI)
Publication: 10.1038/nm1295 (DOI)
Publication: 10.1016/j.endmts.2020.100059 (DOI)
Publication: 10.1038/35053000 (DOI)
Publication: 10.1055/S-0029-1216359/BIB (DOI)
Publication: 10.12997/jla.2022.11.2.161 (DOI)
Publication: 10.1016/J.BBRC.2006.10.051 (DOI)
Publication: 10.1038/nm788 (DOI)
Publication: 10.1161/01.ATV.14.1.32 (DOI)
Publication: 10.3164/jcbn.15-143 (DOI)
Publication: 10.1016/j.cca.2020.11.010 (DOI)

References

  • Al-Azzam SI, Alkhateeb AM, Alzoubi KH, Alzayadeen RN, Ababneh MA, Khabour OF (2013) Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes. Experimental and Therapeutic Medicine 6: 1565–1569. https://doi.org/10.3892/etm.2013.1347
  • American Diabetes Association AD (2018) 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018. Diabetes care 41: S13–S27. https://doi.org/10.2337/dc18-S002
  • Anon (n. d.) Diagnosis | ADA (2023) Anon (n. d.) Diagnosis | ADA. https://diabetes.org/diabetes/a1c/diagnosis [September 14, 2023]
  • Askin L, Abus S, Tanriverdi O (2022) Resistin and cardiovascular disease: A review of the current literature regarding clinical and pathological relationships. Current Cardiology Reviews 18: 1–7. https://doi.org/10.2174/1573403X17666210729101120
  • Babiikir Eltahir H, Mohamed Ali E, Osman Mohamed A (2020) Association of serum adipokines levels with glycemic control and metabolic dyslipidemia in Sudanese patients with type 2 diabetes mellitus. https://doi.org/10.21203/RS.3.RS-37122/V1
  • Basati G, Pourfarzam M, Movahedian A, Samsamshariat SZ, Sarrafzadegan N (2011) Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients. Clinics 66: 1129–1135. https://doi.org/10.1590/S1807-59322011000700002
  • Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA (2006) Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in Type 2 diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 28–40. https://doi.org/10.1161/01.ATV.0000191663.12164.77
  • Blüher M (2014) Adipokines – removing road blocks to obesity and diabetes therapy. Molecular Metabolism 3: 230–240. https://doi.org/10.1016/j.molmet.2014.01.005
  • Bornfeldt KE, Tabas I (2011) Cell Metabolism Review Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metabolism 14(5): P575–585. https://doi.org/10.1016/j.cmet.2011.07.015
  • Dos Santos AR de O, Zanuso B de O, Miola VFB, Barbalho SM, Santos Bueno PC, Flato UAP, Detregiachi CRP, Buchaim DV, Buchaim RL, Tofano RJ, Mendes CG, Tofano VAC, Dos Santos Haber JF (2021) Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions. International Journal of Molecular Sciences 22: e2639. https://doi.org/10.3390/ijms22052639
  • Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Reviews 23: 599–622. https://doi.org/10.1210/er.2001-0039
  • Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 115: 911–919. https://doi.org/10.1016/j.jaci.2005.02.023
  • Gasbarrino K, Boutari C, Filippaios A, Gianopoulos I, Daskalopoulou SS, Mantzoros CS (2023a) Adiponectin, diabetes, and the cardiovascular system. In: Johnstone M, Veves A (Eds) Diabetes and Cardiovascular Disease. Contemporary Cardiology. Humana, Cham, 201–255. https://doi.org/10.1007/978-3-031-13177-6_8
  • Gasbarrino K, Hafiane A, Gianopoulos I, Zheng H, Mantzoros CS, Daskalopoulou SS (2023b) Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis. Metabolism 140: e155381. https://doi.org/10.1016/j.metabol.2022.155381
  • Goyal T, Mitra S, Khaidakov M, Wang X, Singla S, Ding Z, Liu S, Mehta JL (2012) Current concepts of the role of oxidized LDL receptors in atherosclerosis. Current Atherosclerosis Reports 14: 150–159. https://doi.org/10.1007/s11883-012-0228-1
  • Gu X, Wang L, Liu S, Shan T (2023) Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis. Metabolism 139: e155379. https://doi.org/10.1016/j.metabol.2022.155379
  • Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR (2007) The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194: 245–252. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2006.08.002
  • Hsueh WA, Quiñones MJ (2003) Role of endothelial dysfunction in insulin resistance. The American Journal of Cardiology 92: 10–17. https://doi.org/10.1016/S0002-9149(03)00611-8
  • Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43: 1318–1323. https://doi.org/10.1161/01.HYP.0000129281.03801.4B
  • Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3–19. https://doi.org/10.1007/s00125-002-1009-0
  • Katakami N (2018) Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. Journal of Atherosclerosis and Thrombosis 25: 27–39. https://doi.org/10.5551/jat.RV17014
  • Kim KH, Zhao L, Moon Y, Kang C, Sul HS (2004) Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proceedings of the National Academy of Sciences 101: 6780–6785. https://doi.org/10.1073/pnas.0305905101
  • Kishida K, Funahashi T, Shimomura I (2012) molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocrine, Metabolic & Immune Disorders – Drug Targets 12: 118–131. https://doi.org/10.2174/187153012800493468
  • Lambie M, Bonomini M, Davies SJ, Accili D, Arduini A, Zammit V (2021) Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. Trends in Endocrinology and Metabolism 32: 721–730. https://doi.org/10.1016/j.tem.2021.06.001
  • Lee J, Kim B, Kim W, Ahn C, Choi HY, Kim JG, Kim J, Shin H, Kang JG, Moon S (2021) Lipid indices as simple and clinically useful surrogate markers for insulin resistance in the U.S. population. Scientific Reports 11: 1–9. https://doi.org/10.1038/s41598-021-82053-2
  • Li Y, Wang Y, Li Q, Chen Y, Sun S zhen, Zhang W dong, Jia Q (2007) Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 14: 207–214. https://doi.org/10.1080/10623320701617225
  • Lopez LR, Hurley BL, Simpson DF, Matsuura E (2005) Oxidized low-density lipoprotein/β2-glycoprotein i complexes and autoantibodies in patients with type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1051: 97–103. https://doi.org/10.1196/annals.1361.050
  • Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, Peetz D, Post F, Lackner KJ, Tiret L, Münzel T, Blankenberg S (2007) Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 193: 121–128. https://doi.org/10.1016/j.atherosclerosis.2006.05.039
  • Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R (2008) Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes 57: 980–986. https://doi.org/10.2337/db07-1419
  • Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN (2021) Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines 9: e915. https://doi.org/10.3390/biomedicines9080915
  • Myeong JY, Gha YL, Chung JJ, Young HA, Seung HH, Jae BK (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator–activated receptor α. Diabetes 55: 2562–2570. https://doi.org/10.2337/DB05-1322
  • Nazik MA, Azmi TA, Erika SF, Anwar MSB, Musdaq MH, Kamel MA (2008) Prevalence of Dyslipidemia in Patients with Type 2 Diabetes in Jordan. Saudi Medical Journal 29(10): 1423–1428.
  • Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, Catapano AL (2007) Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 38: 2844–2846. https://doi.org/10.1161/STROKEAHA.107.485540
  • Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 11: 85–97. https://doi.org/10.1038/nri2921
  • Park YM (2014) CD36, a scavenger receptor implicated in atherosclerosis. Experimental & Molecular Medicine 46: e99–e99. https://doi.org/10.1038/emm.2014.38
  • Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932–939. https://doi.org/10.1161/01.CIR.0000155620.10387.43
  • Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P (2006) Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clinical Endocrinology 65: 722–728. https://doi.org/10.1111/J.1365-2265.2006.02658.x
  • Shibata R, Murohara T, Ouchi N (2012) Protective role of adiponectin in cardiovascular disease. Current Medicinal Chemistry 19: 5459–5466. https://doi.org/10.2174/092986712803833164
  • Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms. Nature Medicine 11: 1096–1103. https://doi.org/10.1038/nm1295
  • Siddiqui K, Scaria Joy S, George TP (2020) Circulating resistin levels in relation with insulin resistance, inflammatory and endothelial dysfunction markers in patients with type 2 diabetes and impaired fasting glucose. Endocrine and Metabolic Science 1: e100059. https://doi.org/10.1016/j.endmts.2020.100059
  • Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409: 307–312. https://doi.org/10.1038/35053000
  • Tabák AG, Brunner EJ, Miller MA, Karanam S, McTernan PG, Cappuccio FP, Witte DR (2009) Low serum adiponectin predicts 10-year risk of type 2 diabetes and hba1c independently of obesity, lipids, and inflammation: Whitehall II study. Hormone and Metabolic Research 41: 626–629. https://doi.org/10.1055/S-0029-1216359/BIB
  • Tarkhnishvili A, Koentges C, Pfeil K, Gollmer J, Byrne NJ, Vosko I, Lueg J, Vogelbacher L, Birkle S, Tang S, Mwinyella TBN, Hoffmann MM, Odening KE, Michel NA, Wolf D, Stachon P, Hilgendorf I, Wallner M, Ljubojevic-Holzer S, von Lewinski D, Rainer P, Sedej S, Sourij H, Bode C, Zirlik A, Bugger H (2022) Effects of Short Term Adiponectin Receptor Agonism on Cardiac Function and Energetics in Diabetic db/db Mice. Journal of Lipid and Atherosclerosis 11: e161. https://doi.org/10.12997/jla.2022.11.2.161
  • Xu W, Yu L, Zhou W, Luo M (2006) Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochemical and Biophysical Research Communications 351: 376–382. https://doi.org/10.1016/J.BBRC.2006.10.051
  • Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 8: 1288–1295. https://doi.org/10.1038/nm788
  • Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL (1994) Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology 14: 32–40. https://doi.org/10.1161/01.ATV.14.1.32
  • Yoon H, Jeon DJ, Park CE, You HS, Moon AE (2016) Relationship between homeostasis model assessment of insulin resistance and beta cell function and serum 25-hydroxyvitamin D in non-diabetic Korean adults. Journal of Clinical Biochemistry and Nutrition 59: 139–144. https://doi.org/10.3164/jcbn.15-143
  • Zhou L, Li JY, He PP, Yu XH, Tang CK (2021) Resistin: Potential biomarker and therapeutic target in atherosclerosis. Clinica Chimica Acta 512: 84–91. https://doi.org/10.1016/j.cca.2020.11.010